Rapport Therapeutics, Inc. Operating Lease Cost
Rapport Therapeutics, Inc. (RAPP) reported Operating Lease Cost of $2.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-10
- Rapport Therapeutics, Inc. operating lease, cost for fiscal 2025 was $2.75M, a 254.90% increase from fiscal 2024.
- Rapport Therapeutics, Inc. operating lease, cost for fiscal 2024 was $776.00K, a 197.32% increase from fiscal 2023.
- Rapport Therapeutics, Inc. operating lease, cost for fiscal 2023 was $261.00K.
| Period end | Operating Lease, Cost 12 month |
|---|---|
| 2025-12-31 | $2.75M 10-K · filed 2026-03-10 |
| 2024-12-31 | $776.00K 10-K · filed 2026-03-10 |
| 2023-12-31 | $261.00K 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |